Related Experiment Video
Updated: Aug 3, 2026
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Mortality trials with implantable defibrillators
Insights
Future clinical trials comparing antiarrhythmic drugs and implantable cardioverter-defibrillators face ethical challenges due to device efficacy. High-quality data from implantable cardioverter-defibrillators now enable drug efficacy studies without direct patient comparison.
Area of Science:
- Cardiology
- Clinical Trials
- Medical Devices
Background:
- Recent studies show disappointing results with antiarrhythmic drugs for arrhythmias.
- Implantable cardioverter-defibrillators demonstrate excellent long-term outcomes.
- Ethical considerations impede direct comparison trials between drugs and devices.
Abstract:
The continuing disappointing results from recent major studies with antiarrhythmic drugs combined with the continuing excellent outcomes with implantable cardioverter-defibrillators is making it exceedingly difficult, ethically, to conduct future randomized trials comparing the 2 treatment options. On the other hand, the high quality of stored Holter electrograms and the therapy history retrievable from current implantable cardioverter-defibrillators creates opportunities for needed trials on drug efficacy without this ethical dilemma.
